



A Place for Women Menopause Center

Genester S. Wilson-King, M.D., F.A.C.O.G.

0064 6 JAN -3 12:56

January 3, 2006

Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane, Room 1061 (HFA-305)
Rockville, MD 20852

Dear Sir or Madam:

My name is Genester Wilson-King and I have been practicing medicine as an Obstetrician and Gynecologist for 20 years. Furthermore, I have been prescribing bio-identical hormones for my patients for 15 years. BHT (Bio-identical Hormone Therapy) has been a tremendous comfort to them as it alleviates symptoms of hormone imbalance that cause a myriad of chronic and often debilitating problems.

I utilize a team approach in all areas of patient care. I believe patients should be intimately involved in the decision making with regard to management. We (my patient and I) consult with a pharmacist to design and prepare bio-identical hormone therapies specifically for us. Without BHT many patients would suffer from hormone imbalance and this would lead to morbid chronic diseases. I have many patients for which conventional (pharmaceutical) hormone therapy, and non-hormone therapy did not help. These patients were greatly helped with BHT. I would be more than happy to provide more detailed information upon request. I would also welcome the opportunity to discuss this issue with you in person.

The benefit of BHT is that it is designed for individuals. I am concerned that Wyeth's petition (Docket#2005P-0411) would limit my ability to keep prescribing these individualized doses for my patients. As a result, the FDA should reject Wyeth's petition.

Sincerely,

Genester Wilson-King, MD, FACOG

2005P.0411

C143

1502 N. Donnelly Street * Suite 101 * Mt. Dora, Florida 32757

Phone: 352-735-7778 * Fax: 352-735-4045

www.apfwrma.com